Cases

Eric C. Tostrud, United States District Court Prime Therapeutics LLC ("Prime") seeks a preliminary injunction forbidding a former employee, Ashley D. Beatty ("Beatty"), from performing some (but not all) activities in a new job she began recently with Maxor National Pharmacy Services, LLC ("Maxor"). Prime alleges that, if not limited by an injunction, Beatty will inevitably disclose Prime's confidential business information to Maxor. Accordi

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SORRENTO THERAPEUTICS, INC., a ) Delaware corporation, and SCILEX ) PHARMACEUTICALS INC., a Delaware ) corporation, ) ) Plaintiffs, ) ) v. ) C.A. No. 2021-0210-PAF )

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE GREGORY J. PARSEGHIAN as trustee ) of THE GREGORY J. PARSEGHIAN ) REVOCABLE TRUST and ) CHRISTINE M. PARSEGHIAN as ) trustee of THE CHRISTINE M. ) PARSEGHIAN REVOCABLE TRUST, ) ) Plaintiffs, ) ) v. ) C.A. No. 2021-05

Re: D.I. 654 KEVIN GROSS, U.S.B.J. The Court is ruling on McKesson Corporation's ("McKesson") and its wholly owned subsidiary McKesson Patient Relationship Solutions' ("MPRS") Motion for an Order Determining that McKesson is Entitled to the Disputed Funds (the "Motion") *12(D.I. 654). McKesson seeks to affec

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SORRENTO THERAPEUTICS, INC., a ) Delaware corporation, and SCILEX ) PHARMACEUTICALS INC., a Delaware ) corporation, ) ) Plaintiffs, ) ) v. ) C.A. No. 2021-0210-PAF )

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MACROPHAGE THERAPEUTICS, INC., ) a Delaware corporation, ) ) Plaintiff, ) ) v. ) C.A. No. 2019-0137-JRS ) MICHAEL M. GOLDBERG, M.D., and ) M1M2 THERAPEUTICS, INC., ) ) Defendants. )

Newman, Circuit Judge, dissenting. The Patent Trial and Appeal Board, on remand from the Federal Circuit, rejected this Court's remand instruction to implement the Supreme Court's holding in SAS Institute . The Board's action departs from principles of appellate review, and negates the agency's obligations under the America Invents Act. From my colleagues' endorsement of these irregular positions,

United States Court of Appeals For the First Circuit No. 20-1161 AKEBIA THERAPEUTICS, INC., Plaintiff, Appellant, v. ALEX MICHAEL AZAR, II, in his official capacity as Secretary of Health and Human Services, ET AL., Defendants, Appellees. APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

MIRANDA M. DU, UNITED STATES DISTRICT JUDGE Before the Court is Magistrate Judge Nancy J. Koppe's Report and Recommendation ("R & R" or "Recommendation") (ECF No. 20), recommending that this case be remanded for lack of subject matter jurisdiction. Defendants had until June 7, 2018, to file an objection. (Id.at 20.) To date, no objection to the R & R has been filed. Accordingly, the Court adopts the R & R with r

Filed 11/17/21 CERTIFIED FOR PUBLICATION COURT OF APPEAL, FOURTH APPELLATE DISTRICT DIVISION ONE STATE OF CALIFORNIA NEURELIS, INC., D077984 Plaintiff and Respondent, v. (Super. Ct. No. 37-2019- 00064665-CU-BT-CTL) AQUESTIVE THERAPEUTICS, INC., Defendant and Appel

KATHERINE POLK FAILLA, District Judge: On November 29, 2016, Plaintiffs Manchester Management Company, LLC, Manchester Alpha, L.P., JEB Partners, L.P., James E. Besser, and Donald Besser (collectively, "Plaintiffs") filed a complaint in this District along with an ex parte application for a temporary restraining order ("TRO"). In their complaint, Plaintiffs claimed that they had been misled in their purchase of securities i

KAYATTA, Circuit Judge. The price of the publicly traded securities issued by Sarepta Therapeutics, Inc. dropped sixty-four percent when Sarepta announced that the Food and Drug Administration deemed premature Sarepta’s application for approval of a novel gene therapy. Promptly thereafter,. several shareholders brought this securities fraud class action against Sarepta as well as

HONORABLE PAUL A. CROTTY, United States District Judge: This is a securities case brought by buyers of stock in Stemline Therapeutics, Inc. ("Stemline"), which develops a highly sophisticated and complicated drug for the treatment of an otherwise fatal blood cancer. The buyers contend they were misled by Stemline's claimed ability to remediate certain fatal side effects of its drug. Lead Plaintiffs Adam Ludlow, Dalji

Opinion dissenting filed by Circuit Judge NEWMAN Opinion for the court filed by Circuit Judge TARANTO. *1313Before us are patents that claim the administration of a medication containing the active ingredient 4-aminopyridine (4-AP) to improve walking in individuals with multiple sclerosis. Acorda Therapeutics, Inc., holds

FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT KARIM KHOJA, on behalf of himself No. 16-56069 and all others similarly situated, Plaintiff-Appellant, DC No. 3:15-cv-00540- v. JLS OREXIGEN THERAPEUTICS, INC.; JOSEPH P. HAGAN; MICHAEL A. OPINION NARAC

EDWARD M. CHEN, United States District Judge Plaintiff Medical Diagnostics Labs alleges that Defendant Protagonist Therapeutics, Inc.'s development of a drug called PTG-200 infringes on its patent for polypeptides that bind to IL-23 receptors. These polypeptides, including PTG-200, have therapeutic potential to treat inflammatory and autoimmune diseases. Protagonist has entered into a multi-million dollar agreement with third-party

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAVERICK THERAPEUTICS, INC., ) ) Plaintiff, ) ) and ) ) MILLENNIUM PHARMACEUTICALS, ) C.A. No. 2019-0002-SG INC. ) ) Plaintiff-Intervenor, ) ) v.

MEMORANDUM OPINION ‘ REGGIE B. WALTON, United States District Judge This' cáse arises from a dispute over the ownership of two patents that were cooperatively developed by the plaintiff, United Therapeutics Corporation (“United Therapeutics”), and the defendants, Vanderbilt University (“Vanderbilt”) and Dr. James E. Loyd. See Complaint (“Compl.”) ¶¶ 1, 3

723 F.Supp.2d 665 (2010) DESTON THERAPEUTICS LLC and Unigen Pharmaceuticals Inc., Plaintiffs, v. TRIGEN LABORATORIES INC. and Irisys Inc., Defendants. Civil No. 09-809 (JBS/KW). United States District Court, D. Delaware. July 12, 2010. *667 Rodger Dallery Smith, II, Esq., Katharyn A. Grant, Esq., Saul H. Perloff, Esq., Morris, Ni

429 B.R. 570 (2010) In re INTROGEN THERAPEUTICS, INC., Introgen Technical Services, Inc., Debtors. Nos. 08-12442-CAG, 08-12443-CAG. United States Bankruptcy Court, W.D. Texas, Austin Division. April 29, 2010. *573 Andrew S. Brown, Patricia Baron Tomasco, Vanessa E. Gonzalez, Munsch Hardt Kopf & Harr, P.C., Austin, TX, for Debtor.